Sun Pharmaceutical Industries Limited (SUNPHARMA) — Announcement | 24 July 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Organon shareholders approve merger with Sun Pharma
💡 Investor Takeaway
The deal moves Sun Pharma closer to expanding its global footprint through Organon's specialty portfolio.

Sun Pharmaceutical announced that Organon shareholders approved the merger plan to make Organon a wholly owned subsidiary of Sun Pharma's US holding company, marking a key milestone toward closing the transaction subject to customary conditions and regulatory approvals.

📄 View Original Announcement (PDF)

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SUNPHARMA — Free

Free account · 2 AI queries/day